Stay updated with breaking news from Segmentation By Indication. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Antisense & RNAi Therapeutics Global Market Report 2022: By Technology, By Route, By Indication" report has been added to...
The dementia drugs market is expected to expand due to the rising prevalence of dementia and neurological disorders, such as vascular dementia, along with...
/PRNewswire/ -- The "Alpha Mannosidosis Global Market Opportunities And Strategies To 2030, By Therapy Type, Indication, End-User" report has been added to...
Share this article Share this article ResearchAndMarkets.com's offering. Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc. The global trastuzumab biosimilars market is expected to decline from $1.27 billion in 2019 to $1.25 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, r...
Share this article Share this article ResearchAndMarkets.com's offering. Antisense & RNAi Therapeutics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market. Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd. The ...